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Introduction: Hypoglycaemia is a potential lethal complication
of hypoglycaemic medications for patients with Diabetes Mellitus
(DM), as was demonstrated in the Diabetes Control and Compli-
cation Trial (DCCT). United Kingdom Prospective Diabetes
Study (UKPDS) reported an annual incidence of major hypogly-
caemic events of 2.3% in that receiving insulin therapy.
Objective: To evaluate the effectiveness of the Cardiac Diabetic
Nurse in Reducing the Incidence of Hypoglycaemic Events in Car-
diac Patients with Type 2 DM at KACC.
Methodology: This prospective study will implement two inter-
ventions. The ﬁrst will focus on an intensive educational strategy
for approximately 100 cardiac nurses, and facilitate delivery of
the latest evidence based guidelines over a 6-week period. A pre-
test evaluation will be obtained from the cardiac nurses on hypo-
glycaemia management and this will be repeated after the educa-
tion intervention is complete. The second intervention will
address timing of patient snacks and a pre and post audit will
be instigated to evaluate any improvement in deﬁcit areas.
Results: In September and October, 2010 in KACC, 40 patients
had documented hypoglycaemic events. After the intervention
phase we will conduct an observation to detect the number of
hypoglycaemia in December 2010 and January 2011 to evaluate
effectiveness of this intervention.
Conclusion: Cardiac diabetic nurse is effective in reducing the
incidence of hypoglycaemic events in cardiac patients with type
2 DM at KACC through focused educational interventions.
doi:10.1016/j.jsha.2011.02.093
SHA 093. Prevalence of depression in adult Saudi patients with
heart failure King Abdulaziz Medical City
Dalia Ali, Bassam Bdeir, Tara Conboy
King Abdulaziz Medical City-Cardiac Center, Riyadh, Saudi Arabia
E-mail address: alida@ngha.med.sa (D. Ali)
Background: Depression is a common co-morbid condition in
patients with heart failure (HF). Most studies have been done in
Western populations; there are currently no studies on depression
prevalence in HF patients in Saudi Arabia.
Objectives: To explore the prevalence of depression in the adult
Saudi population with HF attending the nurse led clinic at King
Abdulaziz Medical City.
Methods: A retrospective study was carried out included 148
patients with completed electronic data, and patient health ques-
tionnaire (PHQ). All patients were attending the nurse led HF
clinic at KAMC and had at least one visit from May 2010 to Octo-
ber 2010. Depression was assessed using the validated and Arabic
version of the (PHQ).
Results: A total of 72% of the population were male, 32% of
patients experienced varying degrees of depression: 67% with mild,
19%moderate, 8%moderate to severe and 6% with severe depres-
sion. Depression present in 54% of females and 24% of males.
Conclusion: The prevalence of depression in patients with HF
who followed in nurse led clinic is 32.4% and it’s more prevalent
in females.
doi:10.1016/j.jsha.2011.02.094
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Background: The guidelines recommend using spironolactone
in moderate to severe heart failure (HF) and reduced left ventric-
ular systolic function, if there is no contraindication. Spironolac-
tone was shown to have a signiﬁcant mortality and morbidity
beneﬁt in the placebo-controlled trails.
Objective: To study the frequency and causes of discontinuing
spironolactone in Saudi HF patients in HF nurse-led clinic at King
Abudalaziz Medical City (KAMC) Cardiac Center.
Method: A retrospective observational study which included
all patients with HF enrolled from 2000 to 2010 who were pre-
scribed spironolactone at any period and had at least one fol-
low-up visit.
Results: A total of 565 patients (49% male, mean age 55.6
years) were included in this study. Spironolactone was discontin-
ued in 277/565 patients (49%); 187/565 patients (33%) were
discontinued secondary to improved ejection fraction (EF) and/
or functional class; 83/565 patients (14.3%) were stopped due
to worsening renal function and/or hyperkalemia; other side ef-
fects such as hypotension, gyncomastia affected the remaining
<1%.
Conclusion: Nearly half of Saudi HF patient discontinue Spiro-
nolactone within 2 years; the majority of the discontinuation is due
to improved EF or/and functional class.
doi:10.1016/j.jsha.2011.02.095
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Background: Current smoking is a powerful independent pre-
dictor of morbidity and mortality in patients with left ventricular
failure (LVF). Quitting smoking appears to have a substantial and
early effect (within 2 years) on decreasing morbidity and mortality
in patients with LVF, which is at least as effective as proven drug
treatments for heart failure (HF).
Objective: To compare all cause mortality in HF patients who
are current smokers or ex-smokers who quit smoking <2 years
(group 1) with ex-smokers who quit smoking >2 years or never-
smoked (group 2).
Method: This is retrospective observational study to evaluate
the impact of the smoking status on all cause mortality for HF pa-
tients who enrolled in nurse led HF clinic at KACC in 2000 and
2001.
Results: There were 130 patients were enrolled between Janu-
ary 2000 and December 2001 mean age 55 years; 71.5% were male;
total mortality 33/130.
In Group 1 mortality was 8/22 compared to group 2 mortality
which was 25/108 patients univariate and multivariate analysis will
be conducted.
Conclusion: All cause mortality is higher in HF patient who
smoke.
doi:10.1016/j.jsha.2011.02.096
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